Name | 3-(3,4-Dimethoxyphenyl)propionic acid |
Synonyms | DiMethoxyphenyl)propionic ac 3,4-Dimethoxyhydrocinnamic acid 3-(3,4-dimethoxyphenyl)propanoate 3,4-DiMethoxy-benzenepropanoic acid 3-(3,4-Dimethoxyphenyl)propionic acid 3-(3,4-dimethoxyphenyl)propanoic acid 3-(3,4-DiMethoxy)phenyl Proponoic Acid 3-(3,4- twoMethoxy phenyl)propionic acid 3,4-Dimethoxyhydrocinnamic acid, 3-(3,4-Dimethoxyphenyl)propionic acid |
CAS | 2107-70-2 |
EINECS | 218-288-3 |
InChI | InChI=1/C11H14O4/c1-14-9-5-3-8(4-6-11(12)13)7-10(9)15-2/h3,5,7H,4,6H2,1-2H3,(H,12,13)/p-1 |
InChIKey | LHHKQWQTBCTDQM-UHFFFAOYSA-N |
Molecular Formula | C11H14O4 |
Molar Mass | 210.23 |
Density | 1.1922 (rough estimate) |
Melting Point | 96-97°C(lit.) |
Boling Point | 309.75°C (rough estimate) |
Flash Point | 132°C |
Solubility | DMSO, Water |
Vapor Presure | 2.56E-05mmHg at 25°C |
Appearance | Light brown-like crystals |
Color | Slightly beige |
BRN | 2696272 |
pKa | 4.71±0.10(Predicted) |
Storage Condition | Sealed in dry,Room Temperature |
Refractive Index | 1.5384 (estimate) |
MDL | MFCD00002774 |
Physical and Chemical Properties | Appearance: White Crystal Melting Point: 97-100 ℃ |
Use | Used as a pharmaceutical Intermediate |
In vivo study | 3-(3,4-Dimethoxyphenyl)propanoic acid (50, 150 mg/kg of iv or 50, 150, 200 mg/kg of orally) achieves concentrations significantly higher than targeted plasma levels for several hours after single 50 to 150 mg/kg doses. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
HS Code | 29189090 |
Hazard Class | IRRITANT |
NIST chemical information | Information provided by: webbook.nist.gov (external link) |
Biological activity | 3-(3,4-Dimethoxyphenyl)propanoic acid is a short-chain fatty acid (SCFAs) with oral activity. 3-(3,4-Dimethoxyphenyl)propanoic acid stimulates gamma globulin gene expression and erythropoiesis in vivo, and can be used for beta hemoglobinopathy and other anemia. |
use | as a pharmaceutical intermediate |